未经证实:SARS-CoV-2会导致严重的急性呼吸道综合症,促使全球需要新的抗病毒治疗和支持治疗这种危及生命的病毒引起的器官衰竭。这项研究旨在帮助开发一种新的传统波斯医学(TPM)药物,并评估其在有主要症状的COVID-19患者中的有效性和安全性。
UNASSIGNED:2022年2月,一项随机临床试验对德黑兰EmamReza(AJA)医院收治的160名确诊为COVID-19的患者进行了研究,伊朗。在他们住院期间,干预组接受了伊朗卫生和医学教育部(MOHME)批准的治疗方案,由伊朗方案组成,无花果;葡萄,红花,Cicerarietinum,Descurainiasophia种子,朱巴,鸡汤,大麦汤,玫瑰水,藏红花,还有肉桂香料.所有患者在人口统计学方面进行了比较,临床,和实验室变量。
UNASSIGNED:将160例COVID-19患者分为干预组和对照组。在基线特征中,干预组与对照组比较差异无统计学意义(p>0.05)。使用SPSS软件版本22,统计分析显示四个症状的显着差异:肌痛,弱点,头痛,咳嗽(p<0.05)。在5天的治疗期间,对照组C反应蛋白显著降低(p<0.05)。
UNASSIGNED:虽然需要更多样本量更大的研究,拟议的组合似乎在治疗COVID-19患者的症状和炎症生物标志物如C反应蛋白方面有效.伊朗临床试验注册(IRCT)IRCT20220227054140N1。
UNASSIGNED: SARS-CoV-2 causes severe acute respiratory syndrome prompting worldwide demand for new antiviral treatments and supportive care for organ failure caused by this life-threatening virus. This study aimed to help develop a new Traditional Persian Medicine (TPM) -based drug and assess its efficacy and safety in COVID-19 patients with major symptoms.
UNASSIGNED: In February 2022, a randomized clinical trial was conducted among 160 patients with a confirmed diagnosis of COVID-19 admitted to Emam Reza (AJA) Hospital in Tehran, Iran. During their hospitalization, the intervention group received a treatment protocol approved by Iran\'s Ministry of Health and Medical Education (MOHME), consisting of an Iranian regimen, Ficus carica; Vitis vinifera, Safflower, Cicer arietinum, Descurainiasophia seeds, Ziziphus jujuba, chicken soup, barley soup, rose water, saffron, and cinnamon spices. All patients were compared in terms of demographics, clinical, and laboratory variables.
UNASSIGNED: One hundred and sixty COVID-19 patients were divided into two groups: intervention and control. In baseline characteristics, there was no significant difference between the intervention and control groups (p>0.05). Using SPSS software version 22, statistical analysis revealed a significant difference in four symptoms: myalgia, weakness, headache, and cough (p<0.05). During the 5-day treatment period, the control group had significantly lower C-reactive protein (p<0.05).
UNASSIGNED: While more research with a larger sample size is needed, the proposed combination appears to be effective in the treatment of symptoms as well as inflammatory biomarkers such as C-reactive protein in COVID-19 patients.Iranian registry of clinical trials (IRCT) IRCT20220227054140N1.